Finerenone (a selective nonsteroidal mineralocorticoid receptor antagonist) and the SGLT2 inhibitor empagliflozin may reduce both kidney and cardiovascular risks in people with chronic kidney disease and type 2 diabetes. It is unknown whether dual therapy with finerenone and empagliflozin is superior to either agent alone. In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School of Medicine, Durham, NC, USA) discusses the design of the CONFIDENCE study which addresses this clinical question.Â
The abstract entitled: ‘Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE)‘Â was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
Questions:
- What are the aims and design of the CONFIDENCE study? (0:17)
- What are the eligibility criteria of the study? (1:37)
- What are the primary and secondary outcome measures? (2:30)
Disclosures: Jennifer Green discloses grant/research support from Boehringer Ingelheim/Lilly, Merck and Roche.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
